A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
Clinical trial NCT02039674 · COMPLETED
Trial details
- NCT number
- NCT02039674
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-21
- Primary completion
- 2016-11-07
- Enrollment
- 267
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.